Navigation Links
Sangamo BioSciences Announces Fourth Quarter And Full Year 2012 Conference Call And Webcast
Date:1/30/2013

RICHMOND, Calif., Jan. 30, 2013 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) today announced that the company will release its fourth quarter and full year 2012 financial results on Wednesday, February 6, 2013, after the market closes. The press release will be followed by a conference call at 5:00 p.m. ET, which will be open to the public via telephone and webcast. During the conference call, the company will review the financial results and discuss other business matters.

(Logo: http://photos.prnewswire.com/prnh/20130102/SF35903LOGO)

The conference call dial-in numbers are 877-377-7553 for domestic callers and 678-894-3968 for international callers. The passcode for the call is 92659211.  Participants may access the live webcast via a link on the Sangamo BioSciences website in the Investors section under Events and Presentations. For those unable to listen in at the designated time, a conference call replay will be available for one week following the conference call, from approximately 8:00 p.m. ET on February 6, 2013 to 11:59 p.m. ET on February 13, 2013. The conference call replay numbers for domestic and international callers are 855-859-2056 and 404-537-3406, respectively. The conference ID number for the replay is 92659211.

About Sangamo
Sangamo BioSciences, Inc. is focused on research and development of novel DNA-binding proteins for therapeutic gene regulation and genome editing. The Company has ongoing Phase 2 clinical trials to evaluate the safety and efficacy of a novel ZFP Therapeutic® for the treatment of HIV/AIDS. Sangamo's other therapeutic programs are focused on monogenic diseases, including hemophilia, Huntington's disease and  hemoglobinopathies such as s
'/>"/>

SOURCE Sangamo BioSciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Sangamo BioSciences Announces Presentation At The Lazard Capital Markets Healthcare Conference
2. Sangamo BioSciences Announces Presentation At The Stifel Nicolaus 2012 Healthcare Conference
3. Sangamo BioSciences Announces Second Quarter 2012 Conference Call and Webcast
4. Sangamo BioSciences Announces Presentation at Seventh Annual JMP Securities Healthcare Conference
5. Sangamo BioSciences Announces Presentations At Upcoming Investor Conferences
6. Sangamo BioSciences Reports First Quarter 2012 Financial Results
7. Sangamo BioSciences Announces First Quarter 2012 Conference Call and Webcast
8. Sangamo BioSciences Announces Fourth Quarter and Full Year 2011 Conference Call and Webcast
9. Sangamo BioSciences Announces Presentation at J.P. Morgan Healthcare Conference
10. Sangamo BioSciences Announces Presentation of New Data from ZFP Therapeutic® Program in Hemophilia B at American Society for Hematology Meeting
11. IntelliCell BioSciences Announces the Addition of Harry Fisch, MD as Director of Urology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... , June 18, 2013 ... investment research firm, announces the initiation of ... French biopharmaceutical company developing and marketing products ... indications.      (Logo: http://photos.prnewswire.com/prnh/20130417/608168) ... report examining the investment merits of BioAlliance ...
(Date:6/18/2013)... ZIONA, Israel , June 18, ... of complex bulk Active Pharmaceutical Ingredients (APIs), generic and innovative ... systems, announced today that the company has been granted a ... is indicated in the US and Europe ... US Patent number 8,410,176 B2 is titled Intermediate ...
(Date:6/18/2013)... 18, 2013 Research ... the addition of the report " DNA ... to their offering.      (Logo: ... basics of human genome variations, development of ... and small sequencers are described as well ...
(Date:6/18/2013)... Scottsdale, AZ (PRWEB) June 18, 2013 ... telemedicine services MeMD, Inc proudly announces the release ... Revolutionizing Health and Fitness ". , MeMD's goal ... the ever-changing landscape of Health 2.0, Health 3.0 ... that will likely transform medical care and the ...
Breaking Biology Technology:Edison Expands French Healthcare Sector Coverage With Initiation of Coverage on BioAlliance Pharma 2Edison Expands French Healthcare Sector Coverage With Initiation of Coverage on BioAlliance Pharma 3Mapi Pharma Granted United States Patent for Pain Relief Medication "Tapentadol" 2DNA Sequencing: Technologies, Markets and Companies - 2013 Report 2MeMD, Inc Releases Infographic Featuring the Top Eight Technologies that are Revolutionizing Health and Fitness Today 2
... Sept. 18 /PRNewswire-FirstCall/-- Biodel Inc. (Nasdaq:,BIOD) today ... program,at the 43rd Scientific Sessions of the ... VIAject(TM) Phase II meal study data ... entitled, "Pharmacokinetics and pharmacodynamics of,insulin VIAject(TM), insulin ...
... Advantage of ... after HIV Infection, RICHMOND, Calif., Sept. 18 /PRNewswire-FirstCall/ ... the presentation of data,demonstrating that human CD4 T-cells can ... zinc finger DNA-binding protein nucleases,(ZFN(TM)) and preferentially survive and ...
... the Increasing Global Need for Genzyme Products, CAMBRIDGE, ... today broke ground on a significant expansion of its,flagship ... project is focused on adding space for manufacturing support,functions, ... The expansion was marked by a ceremony featuring ...
Cached Biology Technology:Biodel Inc. Announces VIAject(TM) Phase II Meal Study Data at the 2007 European Association for the Study of Diabetes Meeting 2Biodel Inc. Announces VIAject(TM) Phase II Meal Study Data at the 2007 European Association for the Study of Diabetes Meeting 3Sangamo BioSciences Presents Data Demonstrating 'In Vivo' Protection Against HIV Infection by CCR5-ZFN Therapeutic 2Sangamo BioSciences Presents Data Demonstrating 'In Vivo' Protection Against HIV Infection by CCR5-ZFN Therapeutic 3Sangamo BioSciences Presents Data Demonstrating 'In Vivo' Protection Against HIV Infection by CCR5-ZFN Therapeutic 4Sangamo BioSciences Presents Data Demonstrating 'In Vivo' Protection Against HIV Infection by CCR5-ZFN Therapeutic 5Genzyme Begins Major Expansion of Boston Manufacturing Facility 2Genzyme Begins Major Expansion of Boston Manufacturing Facility 3Genzyme Begins Major Expansion of Boston Manufacturing Facility 4Genzyme Begins Major Expansion of Boston Manufacturing Facility 5
(Date:6/18/2013)... of DNA and this modification can occur in ... now, scientists believed that this epigenetic phenomenon actively ... team of researchers from the University of Geneva ... at the Faculty of Medicine, reveals that this ... methylation may play both a passive and active ...
(Date:6/18/2013)... of Adelaide shows that weight gain and increased head size ... a higher IQ at early school age. , The study was ... from more than 13,800 children who were born full-term. , The ... that babies who put on 40% of their birthweight in the ... time they were six years of age, compared with babies who ...
(Date:6/17/2013)... with central nervous system infections may well be suffering ... to a study to be published in mBio ... for Microbiology. Researchers have detected the virus in spinal ... nervous system infections of unknown cause, and in an ... and poultry, suggesting animals may serve as reservoirs for ...
Breaking Biology News(10 mins):The secret of DNA methylation 2IQ link to baby's weight gain in first month 2New virus discovered in patients with central nervous system infections 2New virus discovered in patients with central nervous system infections 3
... more than 10 years of cooperative research on ... the USDA Forest Service,s Pacific Southwest Research Station ... Phytophthora ramorum : A Summary of the Literature." ... of topics, including a history of sudden oak ...
... Vegas, NV (Dec. 24, 2010) - Three weeks of ... heart attack returned microRNA activity close to their pre-event ... studied, just six were attributed to exerting the majority ... study four microRNA optimally regulated by Longevinex and ...
... An expert working group of the International ... Clinical Chemistry and Laboratory Medicine (IFCC) has released ... of bone turnover markers (BTMs) in fracture risk ... it identifies research priorities and recommends that specific ...
Cached Biology News:Comprehensive report on sudden oak death 2Longevinex exerts greater influence over genes than resveratrol 2Longevinex exerts greater influence over genes than resveratrol 3Standardized protocols would greatly enhance clinical and research potential of BTMs 2
When added to either StemSep CD4+ or CD8+ T Cell Enrichment cocktails, human CD69 TAC is designed to deplete human CD69 from samples to isolate resting CD4+ or CD8+ T cells....
This bispecific antibody complex has been tested for efficient depletion of CD41+ cells using the StemSep ; negative immunomagnetic cell separation system....
... is a modular confocal system that gives ... ultra-compact and lightweight design. The improved scan ... performance to 400nm andits bi-directional scanner provides ... X and Y scan axes rotation and ...
... COOLSCOPE is an integrated digital microscope ... a computer, equipment setup, optical adjustment or ... and innovative technology, COOLSCOPE combines simplicity and ... The COOLSCOPE offers simultaneous viewing of a ...
Biology Products: